Nab-paclitaxel
How it works
Nab-paclitaxel is a formulation of paclitaxel that is attached to albumin, which helps it to be more easily absorbed by cancer cells. It works by interfering with the microtubules in cancer cells, which are necessary for cell division, and eventually leads to cell death.
Cancer types
Efficacy
In clinical trials, nab-paclitaxel in combination with gemcitabine improved overall survival and response rates in patients with pancreatic cancer, with approximately 35% of patients achieving a partial response.
Side effects
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination Therapy Shows Promise for Small-Cell Lung Cancer | Lung Cancer | phase-2 | The median progression-free survival was 6.0 months in the ANNAB group and 4.7 months in the NAP group (p = 0.0004). | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for Unresectable Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Fostamatinib with Chemotherapy in Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Treatments for Ovarian Cancer | Ovarian Cancer | observational | The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer | Ovarian Cancer | phase-2 | A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel. | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining Radiation and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-1 | The median overall survival was 22.3 months. | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| Rare Side Effect of Cancer Treatment Affects Vision | Pancreatic Cancer | observational | — | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Combining Nadunolimab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The median overall survival was 13.2 months, and the 1-year survival rate was 58%. | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
| Factors Affecting Chemotherapy-Induced Peripheral Neuropathy in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | — | Source → |
| Combining two treatments may slow pancreatic cancer growth | Pancreatic Cancer | animal-study | Sel-GemPac enhanced the survival of treated mice compared to controls (p < .05). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.